Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

BACKGROUND: We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). METHODS: In this phase 1b expansion cohort, patients with mACC and prior platinum-based therapy received av...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother Cancer
Glavni autori: Le Tourneau, Christophe, Hoimes, Christopher, Zarwan, Corrine, Wong, Deborah J., Bauer, Sebastian, Claus, Rainer, Wermke, Martin, Hariharan, Subramanian, von Heydebreck, Anja, Kasturi, Vijay, Chand, Vikram, Gulley, James L.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6198369/
https://ncbi.nlm.nih.gov/pubmed/30348224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0424-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items